

Mexico Radiopharmaceuticals Market growth of 10.5% CAGR during the forecast period 2023 - 2032

Cancer is among the leading causes of death in Mexico and its occurrence is increasing. This has also resulted in an increase in need for radiopharmaceuticals.

PORTLAND, OREGON, UNITED STATES, December 1, 2023 /EINPresswire.com/ -- The radiopharmaceuticals is a rapidly growing market in the healthcare industry. The market growth is driven by the increasing occurrence of chronic diseases such as cancer, cardiology,



Mexico Radiopharmaceuticals Market

and other related diseases. In addition, the expanding clinical tourism sector in Mexico drives the growth of the market. Furthermore, the introduction of innovative clinical modern technologies and products in the country has also boosted the development of the radiopharmaceuticals market.

According to a Allied Research Reports study, the Mexico Radiopharmaceuticals Market revenue CAGR of 10.5% from 2023 to 2032. The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investment regions.

Request Sample Copy of the Report: https://www.alliedmarketresearch.com/request- sample/A92817

COVID-19 pandemic Analysis:

The COVID-19 pandemic had a significant impact on lives of the people and the global economy. Therefore, the report covers micro and macro-economic COVID-19 impact analysis. In addition, the study provides a qualitative analysis of impact of COVID-19 on the Mexico radiopharmaceuticals market. Moreover, the report also covers the impact of COVID-19 on the Mexico radiopharmaceuticals market during the pandemic. The report further focuses the key strategies adopted by the key players during the pandemic. Furthermore, the report outlines the impact of COVID-19 on the supply chain.

Market Segmentation:

By Type:

Diagnostic radiopharmaceuticals: These radiopharmaceuticals are used to diagnose diseases and conditions, such as cancer, heart disease, and bone disorders. They work by emitting radiation that can be detected by imaging machines, such as SPECT and PET scanners.

Therapeutic radiopharmaceuticals: These radiopharmaceuticals are used to treat diseases, such as cancer. They work by delivering radiation directly to tumors, killing cancer cells while minimizing damage to healthy tissue.

By Application:

Oncology: Radiopharmaceuticals are used to diagnose and treat a wide range of cancers, including lung cancer, breast cancer, prostate cancer, and leukemia.

Cardiology: Radiopharmaceuticals are used to diagnose and assess heart conditions, such as myocardial perfusion imaging (MPI) and nuclear angiography.

Neurology: Radiopharmaceuticals are used to diagnose and assess brain disorders, such as Parkinson's disease and Alzheimer's disease.

Endocrinology: Radiopharmaceuticals are used to diagnose and assess endocrine disorders, such as thyroid disorders and adrenal gland disorders.

Other applications: Radiopharmaceuticals are also used in other areas, such as pain management, palliative care, and bone and joint imaging.

By Isotope:

Technetium-99m (Tc-99m): Tc-99m is the most common isotope used in radiopharmaceuticals, due to its short half-life, low toxicity, and availability.

lodine-123 (I-123): I-123 is a good choice for imaging the thyroid gland and the brain.

Gallium-68 (Ga-68): Ga-68 is used for imaging tumors and infections.

Fluorine-18 (F-18): F-18 is used for imaging tumors and metabolic processes.

By End User:

Hospitals: Hospitals are the largest end users of radiopharmaceuticals, as they have the infrastructure and expertise to perform nuclear medicine procedures.

Nuclear medicine clinics: Nuclear medicine clinics offer specialized services for the diagnosis and treatment of diseases using radiopharmaceuticals.

Ambulatory surgery centers: Ambulatory surgery centers are increasingly offering radiopharmaceutical procedures for certain indications.

Request for Customization: https://www.alliedmarketresearch.com/request-for-customization/93301

Competitive Landscape:

Farmefluar SA de CV
Promecaps SA
Bioenex SA de CV
Gammaglobulin
Nucleomex SA de CV
Plena Pharma SA de CV
Radiofarm SA de CV
Micro-Innova SA de CV
Sanofi
Grupo Angel

Key Benefits For Stakeholders:

Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.

Analyze the key strategies adopted by major market players in mexico radiopharmaceuticals market.

Assess and rank the top factors that are expected to affect the growth of mexico radiopharmaceuticals market.

Top Player positioning provides a clear understanding of the present position of market players.

Detailed analysis of the mexico radiopharmaceuticals market segmentation assists to determine the prevailing market opportunities.

Identify key investment pockets for various offerings in the market.

Table of Content:

CHAPTER 1: INTRODUCTION

- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits to the Stakeholders
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Impacting Factors
- 3.2.2. Top Investment Pockets
- 3.3. Porter's Five Forces Analysis
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

Buy this Premium Research Report: https://www.alliedmarketresearch.com/purchase-enquiry/93301

Key Questions Answered in the Intelligent Study

What is the market size and growth rate of the global and regional market by various segments?

What is the market size and growth rate of the market for selective countries?

Which region or sub-segment is expected to drive the market in the forecast period?

What Factors are estimated to drive and restrain the market growth?

What are the key technological and market trends shaping the market?

What are the key opportunities in the market?

What are the key companies operating in the market?

Which company accounted for the highest market share?

Why Choose Allied Market Research?

Industries' Best Analysts

Exclusive Product Offerings
Customer Research Services
Dynamics Research Methodology
Comprehensive Reports
Latest Technological Advancements
Value Chain Analysis
Future Market Opportunities
Market Growth Dynamics
Quality Assurance
Post-sales Support
Continuous Report Update

Market Dynamics and Transformations

Economic Downturn Analysis: Impact of Recession in 2023

Pandemic's Influence: Impact of Covid-19 Pandemic

Market Evolution: Recent Developments in the Market with Key Players Announcements

Browse more latest healthcare reports (Get a 20% Discount):

Radiopharmaceuticals Market by Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), by Application (Cancer, Cardiology, Others), by Type (Diagnostic, Therapeutic), by End User (Hospitals and clinics, Medical Imaging centers, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

<u>Italy Radiopharmaceuticals Market</u> by Radioisotope (Technetium 99m, Fluorine 18, Iodine I, Gallium 68, Others), by Application (Cancer, Cardiology, Others), by Type (Diagnostic, Therapeutic), by End User (Hospitals and clinics, Medical Imaging centers, Others): Opportunity Analysis and Industry Forecast, 2023-2032

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the

reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+ +1 800-792-5285
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/672212299

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.